Purpose of review Platelet-rich plasma has become an increasingly popular treatment option within the orthopedic community to biologically enhance and stimulate difficult-to-heal musculoskeletal tissues. This review evaluates the recent literature on plateletrich plasma use in the treatment of foot and ankle pathologies. Recent findings Recent literature has demonstrated platelet-rich plasma to have a possible benefit in the treatment of Achilles pathology, chronic plantar fasciitis, osteochondral lesions of the talus, ankle osteoarthritis, and diabetic foot ulcers. However, given the lack of standardization of platelet-rich plasma preparations and protocols and the predominance of low-quality studies, no definitive treatment indications exist. Summary Platelet-rich plasma is a promising treatment option, but at present, there is only limited clinical evidence supporting its use in foot and ankle applications.
Introduction
Platelet-rich plasma (PRP) preparations were first described in the 1980s as plasma with a platelet count above that found normally in peripheral blood [1] . First used in the field of hematology, PRP use has expanded throughout the fields of dermatology, oral-maxillofacial surgery, plastic surgery, cardiac surgery, ophthalmology, urology, and gynecology [2] . However, PRP's predominant use has remained in the field of orthopedics as a treatment for both acute and chronic musculoskeletal pathologies.
Signaling molecules secreted by platelets include growth factors and cytokines which have downstream effects on local inflammatory reactions, recruitment and proliferation of stem cells, cell adhesion, and angiogenesis [3] . These molecules include platelet-derived growth factor, vascular endothelial growth factor, fibroblast growth factor, insulin-like growth factors I and II, transforming growth factor beta, interleukin 8, and matrix metalloproteinases 2 and 9. By concentrating these molecules in PRP preparations and delivering them selectively to injured tissue, it is thought to enhance the natural healing response.
By nature of being an autologous blood concentrate, PRP has been categorized by the FDA as a minimally manipulated tissue and thus has been able to avoid the expensive premarket review and approval process required of other novel treatments [4] . This relatively light regulation, promising early in vitro and animal studies, and celebrity endorsements have fueled the current PRP boom [5] [6] [7] [8] [9] [10] . Despite the increased use and popularity of PRP, the clinical efficacy of its use remains inconclusive. Clinicians continue to evaluate PRP's applications and effectiveness. This article provides a critical analysis of the recent literature on platelet-rich plasma treatment in orthopedic foot and ankle surgery.
Platelet-rich plasma preparation
Significant variability exists regarding the formulation and production of PRP among commercial systems [11] [12] [13] . Variabilities include platelet concentration, leukocyte concentration, growth factor content, as well as differences in separation and activation methods [14, 15] . Not only do these variabilities exist between subjects and systems, but they are also seen in single subjects using the same commercial system for production [16] . These inconsistencies have made it challenging to compare the available literature on PRP. To take a step toward optimizing the composition of PRP, recent efforts have attempted to determine the role of leukocyte concentration within PRP. Simplistically, leukocytes are the primary source of inflammatory cytokines and studies have shown an accumulation of these inflammatory mediators including IL-1 β, TNF-α, IL-6, and IL-8 in leukocyte-rich PRP [17] [18] [19] [20] . Numerous studies evaluating the use of PRP in the treatment of tendinopathies have shown a benefit of leukocyte-reduced PRP over leukocyte-rich PRP due to the pro-inflammatory effects of leukocytes [17, [21] [22] [23] [24] [25] [26] . In intra-articular applications, it has been suggested that leukocyte-reduced PRP is more efficacious and safer for the native cells [27] [28] [29] . Ultimately, further clinical and basic science research is necessary to determine the optimal formulation as well as the appropriate therapeutic protocol for each pathology.
Achilles tendon pathology
The Achilles tendon has a poor regenerative capability which makes treatment of Achilles tendon conditions difficult [30] . These conditions can either be acute Achilles tendon ruptures or chronic, degenerative Achilles tendinopathy.
Randomized control trials evaluating the effects of PRP injections for chronic midsubstance Achilles tendinopathy have been sparse and underpowered [30] [31] [32] [33] [34] . A summary of these studies is provided in Table 1 . The pooled data from four randomized control trials was recently evaluated in a systematic review and meta-analysis by Zhang et al. [30, [32] [33] [34] 35 •]. A total of 170 patients with chronic Achilles tendinopathy enrolled in either a PRP injection plus eccentric strengthening group or a saline injection plus eccentric strengthening group [35•] . These groups were evaluated at a final mean follow-up ranging from 3 to 12 months in the included studies. There was no significant difference between the PRP and saline groups regarding Victorian Institute of Sports AssessmentAchilles (VISA-A) scores, ultrasonographic evaluation of tendon thickness, or ultrasound color Doppler activity. Kearney No significant difference between PRP and saline group at 3 months with regard to primary or majority of secondary outcomes. Tendon thickness was significantly increased in the PRP group at 3 months, but no further conclusions could be made owing to a large dropout rate after 3 months.
Level I
Boesen et al., Am J Sports Med, 2017 [34] • Randomized controlled trial evaluating VISA-A scores, VAS, ultrasonographic tendon thickness/vascularity, and muscle-function between high volume injection (HVI), PRP, and saline for the treatment of chronic noninsertional Achilles tendinopathy HVI and PRP showed significant benefit over placebo in all outcome measures at 6, 12, and 24 weeks of follow-up. HVI was significantly better than both PRP and placebo in the short-term (6 and 12 weeks).
Level I et al. compared PRP injection with an eccentric loading program in 20 patients [31] . No significant difference was found between the groups during the first 6 months with outcome measures including VISA-A scores and EuroQol-5D. Guelfi et al. treated 83 cases of chronic noninsertional Achilles tendinopathy with a single PRP injection [36] . At a mean final follow-up of 50.1 months, the authors demonstrated significant improvements in VISA-A scores, Blazina score, and satisfaction index with no reported complications. Monto treated 30 patients with chronic noninsertional Achilles tendinopathy with a single PRP injection and followed American Orthopedic Foot and Ankle Society (AOFAS) scores at 0, 1, 2, 3, 6, 12, and 24 months posttreatment along with MRI and/ or ultrasound [37] . AOFAS scores significantly improved at 3 months and remained significantly elevated at final followup. Pretreatment imaging abnormalities resolved in 27/29 patients at 6 months posttreatment. The above studies were all made up of relatively small sample sizes and future highquality RCTs with larger sample sizes will be required to determine whether PRP injections are a viable or nonviable treatment option for chronic Achilles tendinopathy. In contradistinction to chronic tendinopathy, acute Achilles tendon ruptures present a completely different set of problems for the orthopedic surgeon. Treatment options range from nonoperative treatment to minimally invasive or open surgery [38] . The in vitro benefits of PRP represent an attractive treatment adjunct to operative and nonoperative treatments as an adjunct for tendon and wound healing. High quality studies evaluating the use of PRP in acute Achilles tendon ruptures are extremely limited. Alsousou et al. evaluated 20 patients with an acute Achilles tendon rupture and randomized patients into a PRP treatment group or control group for both operative and nonoperative treatment arms [39] . Patients were followed for 1, 3, 6, 12, and 24 weeks with Achilles Tendon Rupture Score (ATRS), VISA-A, Foot and Ankle Outcome Score (FAOS), and functional ultrasound elastography (FUSE). ATRS, VISA-A, and FAOS scores were all significantly improved in the PRP group and FUSE scanning demonstrated larger, thicker tendons. De Carli et al. evaluated 30 patients surgically treated for Achilles tendon ruptures with and without adjunctive PRP injections [40•] . MRI with contrast evaluation at 6 months postoperatively did show less signal enhancement in the PRP group compared to the control group which could indirectly represent improved tendon remodeling, but this did not result in appreciable clinical differences. There were no differences in VAS, FAOS, and VISA-A scores and no clinical difference in functional tests between the groups. Schepull et al. demonstrated that PRP had no significant effect on acute Achilles tendon repair in terms of elasticity and functional outcomes [41] . However, their results were difficult to interpret given a large degree of variability between patients. Kaniki et al. retrospectively evaluated the use of PRP in nonoperative treatment of acute Achilles tendon ruptures as an adjunct to accelerated functional rehabilitation [42] . They found no benefit to the addition of PRP in terms of strength, ROM, calf circumference, or Leppilahti score. The above studies suggest no significant benefit to the addition of PRP to the operative or nonoperative treatment of acute Achilles tendon ruptures.
Plantar fasciitis
Plantar fasciitis is the most common cause of heel pain in adults [43] . The root cause being repetitive microtrauma resulting in inflammation and degeneration to the origin of the plantar fascia on the calcaneus. Treatment options range from orthotics, splints, stretching exercises, physical therapy, extracorporeal shock wave therapy (ESWT), medications, injectables, or surgical release [43] . Conservative measures remain the first line of treatment, but nonoperative management still fails in 10 to 15% of patients leading to chronic plantar fasciitis. Corticosteroids, autologous blood injection, and ESWT have been used with varying results and are not without risk including rupture of the plantar fascia after corticosteroid injections [44] [45] [46] . PRP is intriguing as an alternative treatment option to promote healing in the plantar fascia without significant risk.
Kumar Jain et al. compared single injections of PRP or corticosteroid in patients with chronic plantar fasciitis [47] . They found that both PRP and corticosteroid lead to significant improvements in VAS scores, modified Roles and Maudsley scores, Foot and Ankle Outcome Instrument core scale, and AOFAS ankle-hindfoot scale, but there was no significant difference between the two groups. Acosta-Olivo et al. demonstrated similar results showing that PRP had an efficacy equal to that of corticosteroids [48] . Aksahin et al. also showed significant improvement in VAS and modified Roles and Maudsley scores for both PRP and corticosteroid injections, but again, no significant difference between the groups. Recent studies comparing PRP versus corticosteroid injections with more long-term follow-up have demonstrated that PRP's effects may be longer lasting than corticosteroids [49] [50] [51] . Monto showed that PRP injections lead to improved AOFAS scores at 3 months and these improvements were maintained at 24 months postinjection [51] . These results were compared to corticosteroids which had an initial improvement in AOFAS scores at 3 months, but down trended back to baseline by 24 months. Jain et al. found similar results in their study looking at modified Roles and Maudsley scores, VAS scores, and AOFAS scores [50] . PRP and corticosteroid had similar scores at 3 and 6 months, but at 12-month followup, PRP was significantly better. The results of the above studies and others were pooled in systematic review and meta-analysis by Singh et al. [52•] . The pooled data showed that PRP resulted in significant improvement over corticosteroid in VAS and AOFAS scores at 3 months, but no difference in pain or function scores at 1-, 6-, or 12-month follow-up. With the data available, it is uncertain whether the proposed limited benefit of PRP for the treatment of chronic plantar fasciitis is enough to offset the cost implications. Further well-designed, long-term, large-scale randomized controlled trials are needed to determine if PRP confers any benefit over corticosteroids.
Osteochondral lesions of the talus
With the advent of improved imaging technology, osteochondral lesions of the talus (OLT) are increasingly recognized as a source of ankle pain. Conservative management is often successful for small lesions, but for larger lesions or lesions that fail conservative treatment, surgical management is required. Surgical options fall broadly into reparative or reconstructive categories. Generally, these strategies have shown good success in short-to medium-term follow up, but valid concerns exist regarding long-term viability [53, 54] . New research is focused on improving the local biological milieu using PRP adjuncts in the setting of reparative or reconstructive procedures.
Guney et al. performed a randomized prospective study comparing patients treated with microfracture surgery alone versus microsurgery combined with PRP [55•] . At an average follow-up of 16.2 months, the authors found that both groups had significantly improved clinical outcomes as measured by AOFAS scores, Foot and Ankle Ability Measure (FAAM), and VAS, but the PRP group had superior outcomes to the microfracture-only group. Of note, the authors of this study excluded patients with a lesion diameter greater than 20 mm. Previous studies have shown that OCD lesions less than 15 mm in diameter were treated successfully with arthroscopic microfracture in the majority of patients [56, 57] . In a prospective randomized control trial, Gormeli et al. also compared AOFAS and VAS scores for OLT after microfracture surgery combined with PRP, hyaluronic acid (HA), and saline as a control group at a mean follow-up of 15.3 months [58] . While all groups exhibited significantly improved outcomes compared to baseline levels, PRP was found to produce significantly improved clinical scores compared to both HA and saline, with HA also being superior to the control group. MeiDan et al. compared clinical and functional outcomes following three intra-articular injections of either PRP or HA [59] . The authors showed that PRP treatment led to significantly better outcomes in pain and function compared to HA at 28 weeks. The evidence for PRP in the treatment of osteochondral lesions of the talus is promising, but further studies are needed to evaluate preparation, protocol, safety profile, and long-term results before a definitive conclusion can be made.
Ankle osteoarthritis
Osteoarthritis (OA) of the ankle is relatively uncommon in comparison to osteoarthritis of the hip or knee [60, 61] . Previous research has demonstrated clinical and functional improvements after intra-articular PRP injections in patients with knee OA [62] [63] [64] . Information regarding the use of PRP in ankle OA is limited to level IV case series. Repetto et al. evaluated 20 patients with symptomatic OA after four weekly PRP injections [65•] . At an average follow-up of 17.7 months, the authors found significant improvements in pain, function, and patient satisfaction. Fukawa et al. administered three PRP injections at two-week intervals to 20 patients with ankle OA [66] . The authors found significant improvement in pain and function up to 24 weeks after treatment. The maximal pain reduction did occur at 12 weeks after which pain began to trend toward baseline levels but remained significantly improved. Given the paucity of current evidence on PRP in ankle OA, no definitive conclusion can be made about its benefit at this time. The limited data does demonstrate some benefit in the short-to medium-term, but this needs to be compared to other injectables (corticosteroid, HA) in long-term, randomized controlled studies.
Osseous healing
The use of PRP for bone regeneration attempts to utilize the concentrated degranulation products of platelets to jumpstart the healing response at fracture and fusion sites around the foot and ankle. Many preclinical studies have shown PRP to be effective in enhancing osteogenesis [10, 67, 68] . However, the translation of the preclinical results to in vivo bone healing has yielded conflicting evidence. Wei et al. performed one of the only recent studies in the foot and ankle literature on PRP and osseous healing [69] . The authors prospectively compared the use of autograft versus allograft with and without PRP in surgically managed displaced intra-articular calcaneal fractures. At long-term follow-up, the AOFAS scores and radiographic parameters of the allograft with PRP group and autograft group were equivalent with both being superior to the allograft alone group. Calcaneal fractures historically have a high union rate, but operative treatment also carries a high risk of wound complications. This study did not comment in enough detail to make any conclusions about wound healing with or without PRP. Bibbo et al. evaluated the use of autologous platelet concentrate (APC) in high-risk foot and ankle surgery patients undergoing elective procedures [70] . The authors defined high-risk patients as active smokers, diabetics with neuropathy, immunologically or nutritionally impaired, prior history of nonunion or delayed union, previous surgery at proposed operative site, and history of open treatment after high-energy trauma. Sixty-two high-risk patients were followed for 6 months with biweekly radiographs for assessment of radiographic union. Patients who received APC alone had a mean time to union of 40 days and patients who were treated with APC and autograft had a mean time to union of 45 days. The authors concluded that APC is a useful adjunct to promote osseous union in high-risk patients undergoing elective foot and ankle surgery. The hypothetical benefit of PRP in osseous healing is exciting, but many more studies are needed before any definitive conclusion can be made to support the use of PRP in human bone regeneration.
Wound healing
Recent studies have evaluated the role of PRP in wound healing [71] [72] [73] [74] [75] . Ahmed et al. compared PRP platelet gel applied twice weekly to daily antiseptic ointment dressing changes in the treatment of diabetic foot ulcers [74] . The platelet gel was prepared by centrifugation and activation at the patient's bedside with thrombin and calcium chloride. Once the platelet gel had formed a gelatinous disc, it was placed over the cleansed wound and nonabsorbable dressing applied. The authors found that PRP had significantly better healing rate and lower wound infection. Martinez-Zapata et al. performed a Cochrane Database systematic review and concluded that PRP may improve healing of diabetic foot ulcers but cautioned that this recommendation was based on low quality evidence [73] . Kane et al. evaluated the use of PRP in wound healing after total ankle arthroplasty [72] . They found no significant difference in wound healing complications between a group who underwent a nonaugmented closure and a group who underwent closure augmented with PRP. SanGiovanni et al. performed a prospective trial on patients undergoing a foot or ankle surgery randomized to wound closure with and without PRP [71] . There was no significant difference in postoperative complications between the groups including delayed wound healing and postoperative infection.
Conclusion
The use of PRP in Achilles pathology, chronic plantar fasciitis, osteochondral lesions of the talus, ankle osteoarthritis, and diabetic foot ulcers has shown some clinical benefit in the available studies. But given the abundance of conflicting and poor-quality evidence, no clear indications for the use of PRP currently exist. The lack of standardization in the PRP preparation and delivery method has contributed to the inconsistent results. Voices within the orthopedic community are calling for standardization of preparation protocols and reporting to allow study comparison and reproducibility [76] . Therapeutic protocols for timing of PRP administration and number of treatments must also be investigated and standardized. Differing pathologies will also likely require different PRP formulations and protocols to address specific biological needs.
However, PRP should not be abandoned as that would risk passing on a potentially effective treatment modality. Instead, further prospective randomized, controlled studies with standardized PRP formulations and protocols tailored to a specific pathology are needed to identify patient populations that can benefit from its application.
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